Candel therapeutics announces patient-reported tolerability data of intraprostatic injections in ongoing phase 3 clinical trial of can-2409 in patients with localized prostate cancer

Needham, mass., oct. 28, 2021 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that data on patient-reported tolerability assessment of intraprostatic injections will be presented in a virtual poster session at the 28th annual prostate cancer foundation scientific retreat.
CADL Ratings Summary
CADL Quant Ranking